CURIS INC
Business
Curis Inc is a clinical-stage biotechnology company developing emavusertib, an orally available small-molecule IRAK4 and FLT3 inhibitor, through Phase 1/2 and Phase 2 trials for relapsed/refractory primary CNS lymphoma and chronic lymphocytic leukemia. The company holds exclusive worldwide licenses to emavusertib and other immuno-oncology programs from Aurigene Discovery Technologies. Curis operates in the United States and internationally, focusing on hematologic malignancies.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues, net | 9 | 11 | 10 | 10 | 11 | |
| Cost of royalties | 45,000 | 98,000 | 212,000 | 300,000 | 500,000 | |
| Research and development | 28 | 39 | 39 | 43 | 35 | |
| General and administrative | 14 | 17 | 19 | 20 | 17 | |
| Total operating expenses | 42 | 55 | 58 | 63 | 53 | |
| Gain on release of liability related to sale of future royalties associated with sale of assets | 27 | 0 | — | — | — | |
| Loss from operations | −6 | −45 | −48 | −53 | −42 | |
| Interest income | 316,000 | 2 | 3 | 1 | 211,000 | |
| Expense related to the sale of future royalties | −2 | −615,000 | −2 | −5 | −4 | |
| Total other income (expense) | −2 | 1 | 919,000 | −4 | −3 | |
| Net loss | −8 | −43 | −47 | −57 | −45 | |
| Net loss per common share, basic (in dollars per share) | −0.58 | −6.88 | −8.96 | −12.14 | 0.5 | |
| Net loss per common share, diluted (in dollars per share) | −0.58 | −6.88 | −8.96 | −12.14 | 0.5 | |
| Weighted average common shares, basic (in shares) | 13 | 6 | 5 | 5 | 92 | |
| Weighted average common shares, diluted (in shares) | 13 | 6 | 5 | 5 | 92 | |
| Unrealized gain (loss) on marketable securities | 0 | −229,000 | 415,000 | −77,000 | −106,000 | |
| Comprehensive loss | −8 | −44 | −47 | −57 | −46 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 20 | 27 | 20 | 40 | |
| Accounts receivable | 0 | 3 | 3 | 3 | 3 | |
| Prepaid expenses and other current assets | 2 | 3 | 2 | 4 | 3 | |
| Total current assets | 7 | 26 | 61 | 92 | 122 | |
| Property and equipment, net | 62,000 | 231,000 | 434,000 | 689,000 | 505,000 | |
| Restricted cash, long-term | 544,000 | 544,000 | 544,000 | 635,000 | 726,000 | |
| Operating lease right-of-use asset | 2 | 3 | 3 | 4 | 6 | |
| Other assets | 2 | 2 | 3 | 2 | 0 | |
| Goodwill | 9 | 9 | 9 | 9 | 9 | |
| Total assets | 20 | 41 | 77 | 109 | 162 | |
| Accounts payable | 6 | 3 | 3 | 3 | 6 | |
| Accrued liabilities | 7 | 7 | 9 | 6 | 6 | |
| Current portion of operating lease liability | 1 | 1 | 1 | 1 | 682,000 | |
| Current portion of liability related to sale of future royalties | 0 | 8 | 9 | — | 0 | |
| Total current liabilities | 14 | 19 | 22 | 10 | 13 | |
| Long-term operating lease liability | 428,000 | 2 | 1 | 3 | 4 | |
| Liability related to the sale of future royalties, net | 0 | 27 | 34 | 49 | 54 | |
| Total liabilities | 15 | 47 | 58 | 62 | 72 | |
| Commitments and contingencies, Note 6 | — | — | — | — | — | |
| Preferred stock, $0.01 par value 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | — | |
| Common stock, $0.01 par value68,343,750 shares authorized, 12,928,853 shares issued and outstanding at December 31, 2025; 34,171,875 shares authorized, 8,487,818 shares issued and outstanding at December 31, 2024 | 129,000 | 85,000 | 59,000 | 48,000 | 916,000 | |
| Additional paid-in capital | 1,253 | 1,234 | 1,216 | 1,196 | 1,182 | |
| Accumulated deficit | −1,200 | −1,240 | −1,196 | −1,149 | −1,092 | |
| Total stockholders equity (deficit) | 5 | −6 | 20 | 47 | 91 | |
| Total liabilities and stockholders equity (deficit) | 20 | 41 | 77 | 109 | 162 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 200,000 | 200,000 | 300,000 | 200,000 | 200,000 | |
| Non-cash lease expense | 1 | 1 | 1 | 1 | 828,000 | |
| Stock-based compensation expense | 4 | 6 | 6 | 7 | 5 | |
| Non-cash activity related to the sale of future royalties prior to the sale of Erivedge | 360,000 | 154,000 | −340,000 | 659,000 | 36,000 | |
| Amortization of premiums and discounts on investments | 0 | −16,000 | −1 | 351,000 | 1 | |
| Accounts receivable | −1 | −555,000 | 181,000 | 249,000 | −181,000 | |
| Prepaid expenses and other assets | 2 | 139,000 | 405,000 | −2 | −2 | |
| Accounts payable and accrued and other liabilities | 3 | −2 | 3 | −4 | 5 | |
| Operating lease liability | −1 | −1 | −1 | −907,000 | −2 | |
| Total adjustments | −20 | 4 | 9 | 2 | 8 | |
| Net cash used in operating activities | −27 | −40 | −38 | −54 | −38 | |
| Purchases of investments | 0 | −18 | −70 | −62 | −93 | |
| Sales and maturities of investments | 0 | 48 | 108 | 95 | 45 | |
| Proceeds from the sale of Erivedge | 3 | 0 | — | — | — | |
| Net cash provided by investing activities | 3 | 29 | 38 | 33 | −48 | |
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs | 15 | 12 | 14 | 6 | 0 | |
| Payment of liability of future royalties, net of imputed interest | −6 | −9 | −7 | −5 | −4 | |
| Net cash provided by financing activities | 10 | 3 | 8 | 867,000 | −4 | |
| Net decrease in cash and cash equivalents and restricted cash | −15 | −7 | 7 | −20 | −90 | |
| Issuance costs in accounts payable | 328,000 | 50,000 | 0 | — | 0 | |
| Cash paid for interest | 2 | 461,000 | 2 | 4 | 4 | |
| Increase in right-of-use assets and operating lease liabilities resulting from lease modification | 0 | −1 | 0 | 191,000 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CURIS INC's CIK number?
CURIS INC's SEC CIK number is 0001108205 (1108205). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CURIS INC's SEC filings?
All of CURIS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CURIS INC last report earnings?
CURIS INC (CRIS) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001108205-26-000059). This is CURIS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is CURIS INC's most recent earnings 8-K?
CURIS INC's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001108205-26-000059. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CURIS INC's latest earnings 8-K →
Look up any company's CIK number →